Personalized Counseling Doubles Smoking Quit Rates Among Cervical Cancer Survivors

More than 30% of cervical cancer survivors continue smoking after diagnosis. That rate is among the highest of any cancer survivor group, and it persists despite clear evidence that smoking increases the risk of recurrence, second cancers, and reduced survival. The problem is not that these women do not know smoking is harmful. It is that quitting is hard, and most smoking cessation programs are not designed for them.

A new randomized trial, published in JAMA Network Open, tested whether a tailored counseling program could close the gap. The results show it can - at least while the counseling lasts.

The MAPS approach: six sessions over twelve months

The trial, led by researchers at UCLA and Moffitt Cancer Center, enrolled 194 women with a history of cervical intraepithelial neoplasia or cervical cancer who were current smokers. All participants received 12 weeks of standard nicotine replacement therapy, including patches and lozenges.

Half were randomized to standard treatment: self-help materials and a referral to a state quitline. The other half received the same nicotine replacement plus up to six personalized sessions of Motivation and Problem-Solving (MAPS) counseling over 12 months. MAPS sessions focus on motivation, coping with cravings, stress management, relapse prevention, and broader lifestyle factors including nutrition and physical activity.

Double the quit rate at one year

At 12 months, 26.5% of women in the MAPS group had quit smoking, compared with 12.5% in the standard treatment group. The personalized counseling roughly doubled the quit rate.

The cost difference was modest. MAPS ran about $523 per participant versus $389 for standard care. The incremental cost worked out to approximately $921 for each additional person who quit - a figure that compares favorably to other smoking cessation programs for cancer patients. The probability that the program was cost-effective exceeded 90% at commonly accepted willingness-to-pay thresholds.

The relapse problem

But the 18-month data tell a more sobering story. Six months after counseling ended, the quit rate in the MAPS group had dropped to 14.3% - barely above the 12.5% in the standard treatment group. The incremental cost per quitter climbed to about $7,458.

This pattern - strong results during active treatment that fade after it ends - is common across behavioral interventions. It suggests that the counseling relationship itself is doing much of the work, and that removing it allows old patterns to resurface.

There was a bright spot within the data. Women who completed four or more counseling sessions showed stronger and more sustained results, with better cost-effectiveness even at 18 months. Engagement, it appears, matters enormously. But engagement is also self-selecting - the women who attended more sessions may have been more motivated to quit regardless of the program.

A cancer-specific cessation gap

Senior author Tina Shih, PhD, director of the Cancer Health Economics Research Program at UCLA Health Jonsson Comprehensive Cancer Center, noted that very few smoking cessation programs have been designed specifically for cervical cancer survivors. Many of these women face low motivation and confidence in quitting, high stress levels, and sometimes a lack of awareness about the connection between smoking and their specific cancer.

Cervical cancer is strongly associated with human papillomavirus (HPV) infection, and some survivors may not fully appreciate that smoking independently raises their risk of recurrence and second malignancies. Tailored counseling can address this knowledge gap directly.

Honest limitations

The trial enrolled 194 women - a reasonable sample for a randomized trial but still modest enough that the results could shift with a larger or more diverse population. The study was conducted at academic cancer centers, and the participants may not be representative of cervical cancer survivors receiving care in community settings or low-resource environments.

The relapse at 18 months raises a genuine question about whether the investment is worthwhile if the benefits prove temporary. The researchers argue that extended counseling periods and strategies to boost engagement could sustain results, but that hypothesis has not been tested. It is also possible that periodic booster sessions, rather than continuous counseling, might maintain quit rates at lower cost.

The study measured only smoking cessation, not downstream health outcomes. Whether quitting at the 12-month mark - even if some participants later relapse - reduces cancer recurrence or improves survival would require a much longer and larger study.

What the data support clearly is this: personalized counseling works for cervical cancer survivors while it is happening, it works at a reasonable cost, and the field now needs to figure out how to make the effects last.